Piper Sandler Sticks to Their Buy Rating for Amneal Pharmaceuticals (AMRX)
In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with ...
PharmiWeb9 天
Alzheimer’s Therapeutics Market Set to Grow at a 9.2% CAGR, Reaching USD 7,359.7 Million ...
Alzheimer’s Therapeutics MarketThe global Alzheimer’s therapeutics market is projected to experience significant growth, with an expected valuation of USD 3,052.3 million in 2023. The market is ...
Dear Doctor: What do long-term, large studies show about the use of statins for women’s ...
There remains controversy in the scientific community about the benefit of statins in women, because women have been less studied than men.
Stacker on MSN10 天Opinion
What steps to take if you are diagnosed with Alzheimer's disease
SaveHealth provides an overview of Alzheimer's disease, including treatment and coping mechanisms for those with the disease ...
Medscape10 天
Alzheimer’s Disease: The Cholinergic Revival
A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...
Amneal Pharmaceuticals Gets FDA Approval for Alzheimer's Treatment and Brain Tumor Drug
Amneal Pharmaceuticals has received approval from the Food and Drug Administration for a dementia treatment and a drug targeting certain types of brain tumors, as well as tentative approval for a drug ...
Amneal gains FDA approval for dementia and oncology drugs
BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), a pharmaceutical company with a market capitalization of $2.64 billion and rated "GREAT" for financial health according to InvestingPro, ...
Amneal gets FDA approval for memantine/donepezil extended-release capsules
Amneal Pharmaceuticals (AMRX) announced that the FDA has approved memantine/donepezil 14-10 mg and 28-10 mg extended-release capsules, which ...